Volume 16 - Issue 6 - June 2008
09/04/2008
CME #135 June 2008
Skin & Aging is proud to bring you this latest installment in its CME series. This series consists of regular CME activities that qualify you for 1 AMA PRA Category 1 Credit. As a reader of Skin & Aging, this...
CME #135 June 2008
Skin & Aging is proud to bring you this latest installment in its CME series. This series consists of regular CME activities that qualify you for 1 AMA PRA Category 1 Credit. As a reader of Skin & Aging, this...
CME #135 June 2008
Skin &...
09/04/2008
The Dermatologist
09/04/2008
Now that a significant percentage of patients are using some form of complementary and alternative medicine — known as CAM — it behooves their physicians to inform themselves about these approaches to better supervise their...
Now that a significant percentage of patients are using some form of complementary and alternative medicine — known as CAM — it behooves their physicians to inform themselves about these approaches to better supervise their...
Now that a significant...
09/04/2008
The Dermatologist
09/04/2008
Our study of plasma skin regeneration in retinoid treated patients was prompted by the post-treatment response of a retinoid user treated with a plasma skin regeneration device by Rhytec, Inc., which had been FDA approved in 2005 for...
Our study of plasma skin regeneration in retinoid treated patients was prompted by the post-treatment response of a retinoid user treated with a plasma skin regeneration device by Rhytec, Inc., which had been FDA approved in 2005 for...
Our study of plasma skin...
09/04/2008
The Dermatologist
09/04/2008
FDA Approvals & News
Scalp Psoriasis Treatment Approved
The FDA has approved the new drug application for calcipotriene 0.005% and betamethasone dipropionate 0.064% (Taclonex Scalp Topical Suspension). Taclonex Scalp is a topical...
FDA Approvals & News
Scalp Psoriasis Treatment Approved
The FDA has approved the new drug application for calcipotriene 0.005% and betamethasone dipropionate 0.064% (Taclonex Scalp Topical Suspension). Taclonex Scalp is a topical...
FDA Approvals &...
09/04/2008
The Dermatologist
Department
Research in Review
09/04/2008
Photodynamic therapy (PDT) using 20% 5-aminolevulinic acid (ALA) (Levulan Kerastick, DUSA Pharmaceuticals, Inc.) received FDA clearance in 1999 for the treatment of non-hypertrophic actinic keratoses (AKs) of the face and scalp.
Photodynamic therapy (PDT) using 20% 5-aminolevulinic acid (ALA) (Levulan Kerastick, DUSA Pharmaceuticals, Inc.) received FDA clearance in 1999 for the treatment of non-hypertrophic actinic keratoses (AKs) of the face and scalp.
Photodynamic therapy (PDT) using...
09/04/2008
The Dermatologist
Derm Dx
09/04/2008
A 33-year-old transgendered male to female presented to the emergency department for evaluation of “multiple growths” on her face, fever and chills.
A 33-year-old transgendered male to female presented to the emergency department for evaluation of “multiple growths” on her face, fever and chills.
A 33-year-old transgendered male...
09/04/2008
The Dermatologist
Coding and Billing
09/04/2008
This quarterly feature series by expert on dermatology coding, documentation and reimbursement Inga Ellzey will focus on relevant coding issues that most dermatologists frequently encounter.
This quarterly feature series by expert on dermatology coding, documentation and reimbursement Inga Ellzey will focus on relevant coding issues that most dermatologists frequently encounter.
This quarterly feature series...
09/04/2008
The Dermatologist
Column
Industry News
09/04/2008
Onset Launches Topical Anesthetic Foam
Onset Therapeutics has announced the launch of Anestafoam, a novel topical foam formulation containing lidocaine 4%. The product —the first and only foam formulation of lidocaine on the...
Onset Launches Topical Anesthetic Foam
Onset Therapeutics has announced the launch of Anestafoam, a novel topical foam formulation containing lidocaine 4%. The product —the first and only foam formulation of lidocaine on the...
Onset Launches Topical...
09/04/2008
The Dermatologist
Chief Medical Editor Message
09/04/2008
Ihad the good fortune to attend a meeting at which pharmacy benefit managers were discussing dermatologic issues. While many of us dermatologists may swear epithets against those we consider managed care functionaries, their discussions of...
Ihad the good fortune to attend a meeting at which pharmacy benefit managers were discussing dermatologic issues. While many of us dermatologists may swear epithets against those we consider managed care functionaries, their discussions of...
Ihad the good fortune to...
09/04/2008
The Dermatologist
Chief Medical Editor Message
09/04/2008
Within the past 8 years, a new cutaneous fibrosing disorder has emerged — one that is still fraught with some mystery.
Nephrogenic systemic fibrosis received its official name in 2005. This month, we offer continuing medical education on...
Within the past 8 years, a new cutaneous fibrosing disorder has emerged — one that is still fraught with some mystery.
Nephrogenic systemic fibrosis received its official name in 2005. This month, we offer continuing medical education on...
Within the past 8 years, a new...
09/04/2008
The Dermatologist
